AF
IBRX icon

Amalgamated Financial’s ImmunityBio IBRX Stock Holding History

Amalgamated Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$48K Buy
+8,577
New +$52.6K ﹤0.01% 2453

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's IBRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in ImmunityBio (IBRX) in Q1 2022: 8,577 shares worth $48K. The stake represents ﹤0.01% of the portfolio and ranks #2453 among its holdings.

149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

  • Amalgamated Financial held 8,577 shares of ImmunityBio worth $48K as of Q1 2022.
  • ImmunityBio was a new Amalgamated Financial position in Q1 2022.
  • ImmunityBio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2453 holding.
  • 149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.